Reply Reference Values for Central Blood Pressure by Cheng, Hao-Min et al.
JACC Vol. 63, No. 21, 2014 Correspondence
June 3, 2014:2297–303
22992. Brotman DJ, Golden SH, Wittstein IS. The cardiovascular toll of stress.
Lancet 2007;370:1089–100.
3. Kawabata K, Kawai Y, Terao J. Suppressive effect of quercetin on acute
stress-induced hypothalamic-pituitary-adrenal axis response in Wistar
rats. J Nutr Biochem 2010;21:374–80.
4. Steptoe A, Gibson EL, Vuononvirta R, et al. The effects of tea on
psychophysiological stress responsivity and post-stress recovery: a rand-
omised double-blind trial. Psychopharmacology (Berl) 2007;190:81–9.
5. Lee JH, Seo YS, LimDY. Provinol inhibits catecholamine secretion from
the rat adrenal medulla. Korean J Physiol Pharmacol 2009;13:229–39.
APPENDIX
The study is presented in more detail in the online version of this article.Letters to the EditorReference Values for
Central Blood PressureWe recently read with great interest the study in the Journal
by Cheng et al. (1) on central (aortic) arterial blood pressure
thresholds. We highly appreciate the ongoing work of our col-
leagues in this research ﬁeld and agree that the establishment
of event-based cutoff values for central systolic pressures is an
important step forward. In addition, we acknowledge the difﬁ-
culties getting there. Studying this impressive piece of work, we
noticed that the calibration procedures for deriving central
pressure differed between the derivation and validation groups. In
particular, brachial mean and diastolic pressures versus brachial
systolic and diastolic pressures were applied for calibration in the
derivation and validation groups, respectively. This approach is
susceptible to biased estimation of central blood pressure. Indeed,
several research groups showed independently that these 2
methods of calibration may lead to absolute differences in central
systolic pressure estimation of up to 15 mm Hg against each other
and compared with catheter measurements (2–4), independent of
measurement device and method. This has to be added to difﬁ-
culties in estimating the “true” mean blood pressure; either using
integrated brachial waveforms, readings from the oscillometric
device, or simple 0.33 or 0.4 formulas. In our experience, using
mean and diastolic pressure leads to similar readings as those
retrieved from pressure-sensor–tipped catheters, whereas the other
approach underestimates aortic systolic pressure (3). Thus, the
potential error in central blood pressure reading might be large and
might compromise classiﬁcation of patients.
Another issue unclear from their paper is whether their Cox
model adjusting for central pressure also adjusted for brachial
pressure. In previous major outcome studies, this was not done (5).
Are their central blood pressure thresholds independent of, that
is to say adjusted for, brachial pressure? Keeping these funda-
mentals in mind, a large reference value project for central pres-
sures, involving more than 85,000 individuals, is nearly completed,
and will provide complimentary information to the data provided
by our esteemed colleagues, particularly regarding central systolic
pressures, obtained with different techniques.*Thomas Weber, MD
Siegfried Wassertheurer, DI Dr
Bernhard Hametner, DI Dr
Annie Herbert, MSc
Pierre Boutouyrie, MD, PhD
Stephane Laurent, MD, PhD
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Central Blood PressureWe thank Dr. Weber and colleagues for their interest in and
comments on our paper (1) and are delighted that they also agree
that establishment of event-based cutoff values for central blood
pressures (BP) is an important step forward.
In the derivation cohort of our study, central BP were estimated,
with carotid BP derived from carotid pressure waveforms calibrated
to cuff brachial mean blood pressure (MBP) and diastolic blood
pressure (DBP). By contrast, central BP in the validation cohort
was obtained from radial pressure waveforms calibrated to cuff
brachial systolic blood pressure (SBP) and DBP, and a validated
generalized transfer function using the SphygmoCor device (AtCor
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2300Medical, West Ryde, New South Wales, Australia). It has been
argued that cuff brachial MBP/DBP should be used in the cali-
bration procedures for radial pressure waveforms to account for the
small brachial-to-radial pressure ampliﬁcation (2). However, cuff
SBP usually underestimates and cuff DBP overestimates the
invasive brachial BP. It is very likely that the calculated cuff MBP
also suffers from a substantial error, no matter whether the 0.33 or
0.4 formula is used. We have demonstrated that whenever the cuff
MBP underestimates the invasive MBP and the cuff DBP over-
estimates the invasive DBP, the pressure waveform calibrated by
cuff MBP/DBP becomes severely compressed and produces a
huge underestimation of the invasive central SBP. Instead, cali-
bration to cuff SBP/DBP produces an acceptable error. We agree
that the potential error in central BP readings might be large and
might compromise the classiﬁcation of patients. However,
noninvasive brachial BP measurements may suffer from the same
error as well (3).
Our study aimed to derive and validate the diagnostic thresholds
of central BP for the diagnosis of hypertension and the corre-
sponding discriminatory power for predicting cardiovascular mor-
tality (1). We didn’t account for the brachial BP in the multivariate
model because we purported to validate the derived central BP
cutoffs for predicting cardiovascular risks. The incorporation of
brachial BP, with its close correlations with central BP, could cause
considerable confusion of the results. However, it is reassuring that,
as shown in the reclassiﬁcation analysis in the Online Table 1 of
our study (1), central BP had an additional contribution to the
prediction of future cardiovascular outcomes across traditional
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Achilles’ Heel of Statins?
Differences Between the New
Cholesterol Treatment Guidelines
and Everyday Clinical PracticeWe read with great interest the American College of Cardiology/
American Heart Association (ACC/AHA) new guidelines on the
treatment of blood cholesterol (1). The guidelines are based on a
thorough evaluation of randomized controlled trials (RCTs), sys-
temic reviews, and meta-analyses of RCTs with atherosclerotic
cardiovascular disease outcomes.
However, the issue of statin-related myopathy (SRM) has been
greatly underestimated, and this contrasts with ﬁndings of obser-
vational studies that suggest that SRM is relatively common (2,3).
The committee states that SRM is rare (w0.01 excess case per 100
statin-treated individuals per year), and this notion is derived
from data from RCTs that have systematically underestimated
SRM for several reasons (4):
1. Application of strict criteria to deﬁne myopathy, such as
creatine kinase (CK) elevation >10 upper limit normal
(ULN) with or without muscle symptoms, which is a rare
manifestation of myopathy. Therefore, the reported inci-
dence of myopathy in most trials was <0.3%, for example,
in the HPS (Heart Protection Study) study, it was 0.11%
(5); in the 4S (Scandinavian Simvastatin Survival Study)
study, 0.27% (6); and so on. Furthermore, in some trials,
myopathy was deﬁned as a persistent increase in CK >10
ULN on 2 consecutive measurements, which reduced even
more the incidence of myopathy. This is the case with the
TNT (Treating to New Targets) trial (7) in which none of
the participants, even on a high statin dose, fulﬁlled the
criteria for myopathy.
2. Failure to systematically report myalgias: in many trials,
patients were not interviewed for mild muscle complaints,
the commonest manifestation of myopathy, or for fatigue,
another form of myopathy.
3. Exclusion of patients most likely to suffer from myopathy,
such as patients with renal or liver insufﬁciency, patients
taking drugs with possible interaction with statins, older
patients, and so on.
4. Exclusion of patients experiencing muscle symptoms during
the open-label run-in phase of the trials. In some of them,
up to 30% of the eligible patients were excluded in pre-
randomization phases because they did not meet randomi-
zation criteria or had adverse events (7).
Observational studies report an incidence of SRM ranging be-
tween 5% and 10% (2,3), and this is consistent with our daily
clinical practice. It is therefore essential to emphasize that SRM is
not uncommon, and when it appears, does not always necessitates
statin discontinuation. In most cases, myalgias are mild, and after
careful clinical evaluation, discussion with the patient, and weigh-
ing the beneﬁts and risk, it is likely that the patient will remain
